 SAN DIEGO--BUSINESS WIRE--La Jolla Pharmaceutical Company Nasdaq: LJPC, which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and nine months ended September 30, 2020. On July 28, 2020, La Jolla completed its acquisition of Tetraphase Pharmaceuticals, Inc. Tetraphase, a biopharmaceutical company focused on commercializing its novel tetra 